RHEUMATRACE Trademark

Trademark Overview


On Tuesday, September 19, 2023, a trademark application was filed for RHEUMATRACE with the United States Patent and Trademark Office. The USPTO has given the RHEUMATRACE trademark a serial number of 79392510. The federal status of this trademark filing is SUBSEQUENT FINAL MAILED as of Thursday, June 12, 2025. This trademark is owned by Nordic Bioscience A/S. The RHEUMATRACE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; development of diagnostic preparations, equipment and tests; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical development for medical and pharmaceutical research services; advice, information and assistance relating to the foregoing
rheumatrace

General Information


Serial Number79392510
Word MarkRHEUMATRACE
Filing DateTuesday, September 19, 2023
Status660 - SUBSEQUENT FINAL MAILED
Status DateThursday, June 12, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDesign and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; development of diagnostic preparations, equipment and tests; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical development for medical and pharmaceutical research services; advice, information and assistance relating to the foregoing

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 1, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNordic Bioscience A/S
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDK

Trademark Events


Event DateEvent Description
Thursday, March 28, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, April 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 14, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, April 5, 2024APPLICATION FILING RECEIPT MAILED
Monday, May 13, 2024ASSIGNED TO EXAMINER
Friday, May 31, 2024NON-FINAL ACTION WRITTEN
Thursday, June 27, 2024REFUSAL PROCESSED BY MPU
Thursday, June 27, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, July 15, 2024REFUSAL PROCESSED BY IB
Thursday, December 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 26, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 13, 2025FINAL REFUSAL E-MAILED
Monday, January 13, 2025FINAL REFUSAL WRITTEN
Monday, January 13, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, January 20, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 28, 2025LIMITATION OF GOODS RECEIVED FROM IB
Thursday, June 12, 2025SUBSEQUENT FINAL REFUSAL WRITTEN
Thursday, June 12, 2025SUBSEQUENT FINAL EMAILED
Thursday, June 12, 2025NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Wednesday, May 28, 2025LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Monday, January 20, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 20, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED